Leo Pharma overhauls structure, management; U.S. patent board takes up another patent on long-acting Copaxone;

@FiercePharma: India's Maharashtra state asks blood banks to send plasma to Reliance Life Sciences in albumin shortage. FiercePharmaAsia story | Follow @FiercePharma

@CarlyHFierce: ICYMI: Jardiance and its CV data? They're no knockout punch for stalwart Januvia, Merck says. Report | Follow @CarlyHFierce

> The Danish specialty drugmaker Leo Pharma is revamping its top management and restructuring operations, setting up three regional divisions while integrating global R&D and administrative functions. Release

> The U.S. Patent and Trademark Office will review a third patent on Teva Pharmaceutical's ($TEVA) long-acting dose of the multiple sclerosis drug Copaxone, according to generics maker Mylan ($MYL), which filed an inter partes challenge at the U.S. agency. Release

> The FDA expanded approval for Merck & Co.'s ($MRK) chemotherapy-related nausea drug Emend for use in some children. Release

> Tesaro ($TSRO) won FDA approval for its first drug, Varubi, a treatment for chemo-related nausea and vomiting in adults. Release

> Allergan ($AGN) said the official FDA labeling on its anti-infective drug Teflaro was updated to support a shorter infusion time. Release

> European regulators gave the green light to Novartis' ($NVS) first-in-class drug Revolade for patients with severe aplastic anemia. Release

Medical Device News

@FierceMedDev: Agena Bioscience opening office in China, aims to sell spectrometry systems in the country. FierceDiagnostics story | Follow @FierceMedDev

@VarunSaxena2: ICYMI: Quanterix and Banyan Biomarkers forge ahead with brain injury diagnostic tech. More | Follow @VarunSaxena2

@EmilyWFierce: DynoSense selects Chinese marketing partner for handheld monitoring device. Story | Follow @EmilyWFierce

> HeartWare looks to diversify into mitral valve repair with $929M purchase of Valtech Cardio. Story

> FDA partners with nonprofit device incubator Fogarty Institute to improve approval efficiency. More

Biotech News

@FierceBiotech: ICYMI yesterday: Gene therapy upstart Audentes bags a new program in buyout. Article | Follow @FierceBiotech

@JohnCFierce: From the early hours file: AstraZeneca backs $80M round for ADC's antibody warhead tech. News | Follow @JohnCFierce

@DamianFierce: ICYMI yesterday: AstraZeneca auctions off troubled psoriasis drug to Valeant in $445M deal. More | Follow @DamianFierce

> Amgen's bone drug beats Lilly's Forteo in a Phase III osteoporosis trial. Report

> In neuroscience swap, Amgen buys into Novartis' BACE drug program for Alzheimer's. More

> Sanofi punts a $200M Ardelyx deal and hands back some preclinical drugs. Article

Biotech Research News

> TGen IDs targets for nonalcoholic fatty liver disease. Item

> Ziopharm tests new approach to engineering CAR-Ts for solid tumors. Report

> Eta-amyloid discovered in Alzheimer's adds new piece to the complex puzzle. More

> New research highlights role of SKA2 gene in PTSD, suicide. Article

> Gene variant linked to a 10-year delay in Alzheimer's onset. Story

Diagnostics News

> FDA scolds Cepheid for manufacturing issues in Sweden. More

> Exact Sciences wins CMS panel vote for Cologuard pricing. Report

> JAMA: Two genetic tests, not one, could work better at diagnosing autism. More

> Agena Bioscience opening office in China, aims to sell spectrometry systems in the country. Story

> FDA scolds Cepheid for manufacturing issues in Sweden. Article

Pharma Marketing News

> Bristol-Myers' Opdivo snags FDA priority review for bigger lung cancer use. Item

> Pharma TV ads are good for the business bottom line, study says. Report

> New Pradaxa antidote study preps Boehringer for market-share turnaround: ESC. Story

> AstraZeneca sales team revving up for new Brilinta marketing push. More

> Valeant bets the odds on AZ's psoriasis med in $100M-plus development deal. Article

And Finally... The FDA warned 5 companies that sell powdered caffeine, saying the products are potentially dangerous. Report

Suggested Articles

AbbVie has seen blossoming market share for immunology launches Rinvoq and Skyrizi—and it's eyeing Allergan's neurology biz for a boost, too.

While Novo's Rybelsus launch has slowed due to the pandemic, another version of the med, Ozempic posted strong sales.

AZ sold Atacand and Atacand Plus rights in about 70 countries to Cheplapharm.